OMI Urges Appeals Court to Allow Antitrust Challenge to Amgen’s Extension of Enbrel Monopoly

OMI Legal filed an amicus brief in the U.S. Court of Appeals for the Fourth Circuit urging the court to allow an antitrust lawsuit, CareFirst v. Amgen, that challenges Amgen’s use of acquired patent rights to extend its monopoly over the blockbuster drug Enbrel.

Open Markets Institute Files Amicus Brief Defending Antitrust Verdict Against Biosense Webster for Exclusionary Conduct in Medical Device Market

The Open Markets Institute filed an amicus brief in the U.S. Court of Appeals for the Ninth Circuit supporting Innovative Health, LLC in Innovative Health v. Biosense Webster urging the court to uphold a jury verdict finding Biosense Webster guilty of violating federal antitrust law by using its dominant position in the cardiac-mapping market to block competition from lower-cost medical device reprocessors.

Three New Ideas That Put Working People First by Reforming Market Power

Healthcare, transportation, and the care economy are each captured by giant corporations or private equity, resulting in higher costs and horrible service. Three new articles from Open Markets staff in the new issue of The Washington Monthly point toward solutions.

Washington Monthly - Corporate-Proof the Care Economy

Industrial policy program manager Audrey Stienon argues that before increasing federal investment in child and elder care, measures should be taken to prevent large corporations from dominating these markets and compromising service quality for working-class families.

Washington Monthly - Medicare Prices for All

Policy director Phillip Longman argues that linking employer-sponsored health insurance rates to Medicare prices could significantly reduce hidden healthcare costs, thereby increasing workers' take-home pay and improving their standard of living.

Monopoly Matters